分组1 - Septerna, Inc. reported a quarterly loss of $0.24 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.23, but an improvement from a loss of $0.64 per share a year ago, indicating an earnings surprise of -5.50% [1] - The company posted revenues of $24.12 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 17.98%, compared to revenues of $0.21 million in the same quarter last year [2] - Over the last four quarters, Septerna has not surpassed consensus EPS estimates, achieving this only once for revenue estimates [2] 分组2 - The stock has increased by approximately 3.2% since the beginning of the year, contrasting with a 1.5% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $20.86 million, and for the current fiscal year, it is -$1.11 on revenues of $82.26 million [7] - The Medical - Biomedical and Genetics industry, to which Septerna belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Financial Position - As of December 31, 2025, the company had an accumulated deficit of $167.3 million and a net loss of $48.9 million for the year ended December 31, 2025[224]. - As of December 31, 2025, the company had $548.7 million in cash, cash equivalents, and marketable securities, which is expected to fund operations at least into 2029[227]. - The company may require substantial additional funding to finance its operations and product development programs[226]. - The company has $45.8 million of federal net operating loss (NOL) carryforwards and $77.9 million of state NOL carryforwards available to reduce future taxable income as of December 31, 2025[338]. Product Development and Clinical Trials - The company has no products approved for commercial sale and has not generated any revenue from product sales to date, continuing to incur significant research and development expenses[224]. - The company expects to continue incurring significant operating losses for at least the next several years as it develops its product candidates[224]. - The company has invested substantially all of its research efforts in developing its Native Complex Platform® and identifying potential product candidates[235]. - The company has not successfully completed any advanced clinical trials to date and has limited experience in managing clinical trials necessary for regulatory approvals[235]. - The company plans to advance SEP-631 in clinical development and is also planning to develop next-generation oral small molecule PTH1R agonists[235]. - The company discontinued development of its previous lead candidate, SEP-786, due to two unanticipated severe (Grade 3) events observed in clinical trials[253]. - The company plans to initiate a placebo-controlled, SAD and MAD Phase 1 clinical trial for its new PTH1R development candidate, SEP-479, in Australia, pending successful regulatory submissions in the first half of 2026[278]. Regulatory Challenges - The company faces risks related to the speculative nature of pharmaceutical product development and the uncertainty of achieving commercial success[225]. - The company may face significant delays in the development and commercialization of product candidates due to various factors, including regulatory approval issues and clinical trial challenges[236]. - Regulatory approval processes are lengthy and costly, often taking many years and requiring substantial evidence from clinical trials[256]. - The FDA may require a boxed warning for product candidates, as seen with NATPARA, which included a warning related to the risk of osteosarcoma[254]. - Regulatory authorities may impose additional requirements or request further data, potentially delaying the approval process for product candidates[240]. - The company must ensure compliance with significant regulatory obligations post-approval, which could incur additional costs and affect financial performance[242]. - The company may face significant delays in obtaining regulatory approvals due to safety concerns raised by regulatory authorities[260]. - The company must demonstrate that product candidates are safe and effective, which may require further preclinical studies or clinical trials[257]. Market and Competitive Landscape - The commercial success of approved products will largely depend on the availability of coverage and adequate reimbursement from third-party payors[241]. - The availability and adequacy of coverage and reimbursement by governmental and private payors are essential for patient affordability and revenue generation[294]. - The company faces substantial competition from major pharmaceutical and biotechnology companies, which may have greater resources and experience[300]. - The total addressable market for the company's product candidates may be smaller than estimated, impacting revenue and business performance[313]. - The company may need to reallocate resources and reprioritize development programs based on evaluations of the competitive landscape[303]. Operational Risks - The company currently lacks a marketing and sales organization and has no experience in commercializing products, which may hinder its ability to generate product revenue[290]. - If product candidates receive marketing approval, the company will need to build a marketing and sales organization, which will be expensive and time-consuming[290]. - The company is highly dependent on its senior management team, and the loss of key personnel could impede its research and commercialization objectives[322]. - The company faces intense competition for qualified personnel, which may limit its ability to achieve development objectives[323]. - The company may incur substantial costs and liabilities due to clinical trial and product liability lawsuits, which could limit the commercialization of product candidates[331]. Compliance and Legal Risks - The company faces risks related to compliance with extensive healthcare laws and regulations, which could result in significant civil, criminal, and administrative penalties[1]. - Compliance with ongoing regulatory obligations post-approval may result in significant additional expenses for the company[266]. - The company is subject to numerous environmental, health, and safety laws and regulations, and failure to comply could result in significant fines or penalties[333]. - The company may not be able to maintain adequate insurance coverage for product liability claims, which could impair business operations[332]. Data Privacy and Cybersecurity - The company faces substantial risks related to cybersecurity incidents, including potential theft or destruction of sensitive data and intellectual property[345]. - The company relies on third-party vendors for cybersecurity measures, which introduces additional vulnerabilities and risks[355]. - Compliance with evolving data privacy and security obligations could lead to significant costs and liabilities for the company[353]. - The company may face significant operational disruptions if unable to transfer personal data from the EEA or U.K. to the U.S. due to legal challenges[384]. Strategic Partnerships and Collaborations - The company relies on collaborations with third parties for product development, and any failure in these collaborations could adversely affect market potential[415]. - The Novo Collaboration Agreement aims to develop multiple oral small molecule therapies for metabolic diseases, with four simultaneous research programs initiated[416]. - Collaborators have significant discretion in resource allocation, which may impact the development and commercialization of product candidates[418]. - The company may face significant challenges if current or future collaborators terminate agreements, potentially leading to independent development of product candidates and adverse effects on business and financial condition[420]. Future Outlook and Strategic Initiatives - The company is pursuing orphan drug designation for its product candidates, particularly for hypoparathyroidism, which affects approximately 70,000 individuals in the U.S., potentially qualifying for exclusivity[366]. - The company may seek Fast Track Designation from the FDA for its product candidates, but there is no guarantee that such designations will be granted or lead to expedited development[368]. - The company plans to pursue the PRIME scheme in the EU for accelerated assessment of product candidates, but eligibility is not guaranteed and can be withdrawn if criteria are not met[369]. - The company is subject to evolving data protection and privacy regulations, which could adversely affect its operations if compliance is not maintained[376].

Financial Performance - Septerna reported a revenue of $24.1 million for Q4 2025, a significant increase from $0.2 million in Q4 2024, and a total revenue of $46.0 million for the full year 2025, compared to $1.1 million in 2024[12] - The company’s cash, cash equivalents, and marketable securities totaled $548.7 million as of December 31, 2025, up from $420.8 million a year earlier, with a cash runway expected to support operations at least into 2029[12] - Net loss for Q4 2025 was $10.7 million, compared to a net loss of $20.7 million in Q4 2024, and the full year net loss was $48.9 million, down from $71.8 million in 2024[12] Research and Development - Research and development (R&D) expenses for Q4 2025 were $31.9 million, compared to $19.3 million in Q4 2024, and total R&D expenses for the full year were $97.6 million, up from $65.3 million in 2024[12] - Septerna plans to initiate a Phase 2b trial of SEP-631 in chronic spontaneous urticaria (CSU) in the second half of 2026, following positive Phase 1 results[6] - Septerna is advancing SEP-479 toward Phase 1 initiation in the first half of 2026, targeting hypoparathyroidism[4] - The company continues to progress its TSHR NAM program, aiming to deliver a potential oral treatment for Graves' disease and thyroid eye disease[6] Collaborations and Payments - The company received a $195.0 million upfront payment from Novo Nordisk and a $12.5 million milestone payment from Vertex during 2025[12] Product Development - SEP-631 demonstrated complete inhibition of wheal formation at doses as low as 10 mg once daily, with near complete inhibition at 90 and 200 mg once daily[6]

Core Insights - Septerna, Inc. has reported positive Phase 1 results for SEP-631, a drug targeting MRGPRX2, which supports its advancement to Phase 2b development in chronic spontaneous urticaria (CSU) in the second half of 2026 [2][8] - The company is also progressing SEP-479, a PTH1R agonist, towards Phase 1 initiation in the first half of 2026 [4] - Septerna's cash runway is expected to support its operations at least into 2029, with cash, cash equivalents, and marketable securities totaling $548.7 million as of December 31, 2025 [12][16] Pipeline Progress and Milestones - SEP-631 has shown a well-tolerated safety profile and robust pharmacodynamics, achieving complete inhibition of wheal formation at doses as low as 10 mg once daily [8] - SEP-479 is on track for Phase 1 clinical trials, having completed IND-enabling studies [4] - The TSHR NAM program is progressing towards candidate selection for potential treatments for Graves' disease and thyroid eye disease [5] - Discovery-stage programs are advancing across multiple therapeutic areas utilizing the Native Complex Platform [6] Financial Highlights - Revenue for Q4 2025 was $24.1 million, a significant increase from $0.2 million in Q4 2024, and $46.0 million for the full year 2025 compared to $1.1 million in 2024 [12][15] - R&D expenses for Q4 2025 were $31.9 million, up from $19.3 million in Q4 2024, and $97.6 million for the full year 2025 compared to $65.3 million in 2024 [12][15] - General and administrative expenses for Q4 2025 were $8.3 million, compared to $5.6 million in Q4 2024, and $29.2 million for the full year 2025 compared to $16.6 million in 2024 [12][15] - The net loss for Q4 2025 was $10.7 million, an improvement from a net loss of $20.7 million in Q4 2024, and the full year net loss was $48.9 million compared to $71.8 million in 2024 [12][15]

Summary of Septerna's Conference Call Company Overview - **Company**: Septerna - **Industry**: Biopharmaceuticals, specifically focused on GPCR (G protein-coupled receptor) drug discovery Key Points and Arguments Pipeline and Drug Development - Septerna is advancing its pipeline, particularly with the MRGPRX2 program, which has shown promising phase 1 data indicating differentiation from existing drugs and effective pharmaceutical properties, including the complete abrogation of the inflammatory cascade [1][4] - The company is also developing an oral PTH (parathyroid hormone) agonist, SEP-479, aimed at treating hyperparathyroidism, which is expected to enter clinical trials soon [1][21] MRGPRX2 Program - The MRGPRX2 program is focused on a negative allosteric modulator, SEP-631, which has demonstrated a potent effect in preclinical models, showing complete knockdown of skin extravasation in response to agonists [5][10] - Phase 1 trial results indicate that SEP-631 was well-tolerated with no serious adverse events, a half-life of approximately 24 hours, and no food effect, suggesting potential for once-daily oral dosing [13][18] - The upcoming phase 2 trial for chronic spontaneous urticaria is planned for the second half of the year, with a focus on dose-ranging and placebo-controlled design [20][31] SEP-479 Program - SEP-479 is a selective small molecule agonist for the PTH1 receptor, aimed at patients who have lost their parathyroid glands, leading to low calcium levels [21][22] - Preclinical studies have shown that SEP-479 can normalize serum calcium levels and has a long projected human half-life of 40-80 hours, with IND-enabling studies nearing completion [23][27] - The phase 1 trial for SEP-479 is set to begin in Australia, with a focus on safety and efficacy in healthy volunteers [28][44] Market Opportunity - Both programs target significant unmet medical needs, with MRGPRX2 involved in various conditions such as chronic spontaneous urticaria, asthma, and atopic dermatitis, while SEP-479 addresses hyperparathyroidism [19][21] - The company is well-capitalized, with a cash runway extending into at least 2029, allowing for continued investment in its pipeline [4] Additional Insights - The Native Complex Platform developed by Septerna is designed to unlock difficult GPCR targets, which has led to a robust portfolio of drug candidates [3][4] - The company is exploring multiple indications for its MRGPRX2 antagonist, including pain conditions and rheumatology indications, beyond the initial focus on chronic spontaneous urticaria [20] - The use of innovative technologies, such as the AllergyScope for quantifying skin wheals, highlights Septerna's commitment to advancing clinical trial methodologies [15] Conclusion - Septerna is positioned to make significant advancements in the biopharmaceutical industry with its innovative drug discovery platform and promising pipeline, particularly in the areas of GPCR-targeted therapies and calcium regulation in hyperparathyroidism. The upcoming clinical trials and strong financial backing suggest a positive outlook for the company's future developments.

Summary of Septerna's Conference Call on SEP-631 Phase I Results Company Overview - **Company**: Septerna (NasdaqGM:SEPN) - **Focus**: Development of GPCR (G protein-coupled receptor) drug discovery, specifically targeting mast cell-driven diseases with their lead compound SEP-631 [2][4] Industry Context - **Target Disease**: Mast cell-driven diseases, including chronic spontaneous urticaria (CSU), atopic dermatitis, interstitial cystitis, migraine, and asthma [10][27][30] - **Market Opportunity**: High unmet medical need for effective treatments in mast cell-related conditions, particularly for patients refractory to current therapies [28][30] Key Points from the Conference Call Phase I Trial Results for SEP-631 - **Trial Design**: Randomized, double-blind, placebo-controlled study with single ascending doses (10 to 400 mg) and multiple ascending doses (10 to 200 mg) [18][19] - **Safety Profile**: - No severe or serious adverse events reported; treatment emergent adverse events comparable to placebo [19][20] - Mild transaminase elevations observed, not dose-related, and comparable to placebo [19][54] - **Pharmacokinetics**: - Elimination half-life of approximately 24 hours, supporting once-daily dosing [20][25] - No food effect observed, allowing for flexible dosing [20][25] Pharmacodynamics and Mechanism of Action - **Target Engagement**: Robust dose-dependent inhibition of MRGPRX2 signaling demonstrated through skin challenge tests [22][23] - **Efficacy**: Complete inhibition of icatibant-induced skin wheel formation at doses as low as 10 mg once daily [24][25] - **Mechanism**: SEP-631 acts as a negative allosteric modulator (NAM) with sub-nanomolar binding affinity, effectively closing the agonist binding pocket of MRGPRX2 [11][12][16] Future Development Plans - **Phase II Initiatives**: - Initiation of a Phase IIb study in chronic spontaneous urticaria planned for the second half of 2026 [27][29] - Exploration of additional indications including chronic inducible urticaria, atopic dermatitis, interstitial cystitis, migraine, and asthma [27][30] - **Clinical Strategy**: Focus on developing cost-efficient clinical plans to demonstrate proof of concept across various mast cell-driven diseases [31] Financial Position - **Capitalization**: Well-capitalized with a cash runway extending into 2029, allowing for continued investment in innovation and advancement of the pipeline [6][33] Strategic Partnerships - **Collaboration**: Ongoing strategic partnership with Novo Nordisk focused on five metabolic targets, enhancing the company's research capabilities [7][32] Additional Insights - **Market Positioning**: SEP-631 is positioned as a potential best-in-class treatment for mast cell-driven diseases, leveraging its unique pharmacological profile and favorable safety data [25][26] - **Research and Development**: Continuous evaluation of new indications and mechanisms related to mast cell activation, with a focus on understanding patient heterogeneity in response to treatments [81][80] This summary encapsulates the critical aspects of Septerna's conference call regarding SEP-631, highlighting the company's strategic direction, clinical findings, and market opportunities in the context of mast cell-driven diseases.

Phase 1 Results* for SEP-631, a Novel Oral Small Molecule MRGPRX2 Negative Allosteric Modulator (NAM) for Mast Cell-Driven Diseases March 2, 2026 Nasdaq: SEPN *Data presented at the 2026 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting © 2026 SEPTERNA Forward-Looking Statements This presentation contains express or implied forward‐looking statements of Septerna, Inc. (the "Company," "we," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. ...

Core Insights - Septerna, Inc. announced positive results from its Phase 1 clinical trial of SEP-631, a selective oral negative allosteric modulator targeting MRGPRX2, demonstrating robust inhibition of icatibant-induced skin wheal formation and well-tolerated across all doses studied [1][2][3] Phase 1 Results - SEP-631 was evaluated in a randomized, double-blind, placebo-controlled Phase 1 trial, showing a favorable pharmacokinetic profile supportive of once-daily oral dosing [3][5] - Complete inhibition of skin wheal formation was observed at doses as low as 10 mg once daily, with dose-dependent inhibition noted at higher doses [3][5] - The adverse event profile was comparable to placebo, with no severe or serious adverse events reported [5] Phase 2 Development Strategy - The company plans to initiate a Phase 2b clinical trial of SEP-631 in chronic spontaneous urticaria (CSU) in the second half of 2026, following ongoing long-term toxicology studies [4][6] - The Phase 2b study will be a randomized, double-blind, placebo-controlled trial evaluating once-daily oral SEP-631 in adult patients with moderate-to-severe CSU [6] Future Indications - Beyond CSU, Septerna is exploring additional mast cell-driven diseases with high unmet medical need, including atopic dermatitis, interstitial cystitis, migraine, and asthma [7][9] Company Overview - Septerna, Inc. is a clinical-stage biotechnology company focused on GPCR-targeted medicines, utilizing its proprietary Native Complex Platform for drug discovery [10]

Core Viewpoint - Septerna, Inc. is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery and will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 [1] Group 1: Company Overview - Septerna, Inc. is advancing GPCR therapies to address significant unmet medical needs [3] - The company utilizes its proprietary Native Complex Platform® to enhance GPCR drug discovery [3] - Septerna has developed a diverse pipeline of novel oral small molecule drug candidates targeting various therapeutic areas including endocrinology, immunology, inflammation, and metabolic diseases [3] Group 2: Presentation Details - Jeffrey Finer, M.D., Ph.D., CEO and co-founder of Septerna, will present at the conference at 3:10 p.m. ET [1] - A live webcast of the presentation will be available on the company's website and archived for at least 30 days [2]

Core Insights - Septerna, Inc. has granted an inducement award to its Chief Legal Officer, Mark A. Wilson, consisting of a non-qualified stock option to purchase 165,000 shares of common stock under the Company's 2026 Inducement Plan [1][2] Group 1: Stock Option Details - The stock option has an exercise price of $25.41 per share, which is equal to Septerna's closing share price on February 6, 2026 [2] - The stock option will vest over four years, with 25% of the shares vesting on the one-year anniversary and the remaining 75% vesting in equal monthly installments over 36 months, contingent on Mr. Wilson's continuous employment [2] Group 2: Company Overview - Septerna, Inc. is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, aiming to address significant unmet medical needs [3] - The company utilizes its proprietary Native Complex Platform to develop a diverse pipeline of novel oral small molecule drug candidates across various therapeutic areas, including endocrinology, immunology, inflammation, and metabolic diseases [3]